Potential of liraglutide in the treatment of patients with type 2 diabetes

Review

(2537) Views  (990) Full article downloads

Authors: Carolyn F Deacon

Published Date February 2009 Volume 2009:5 Pages 199 - 211

DOI: http://dx.doi.org/10.2147/VHRM.S4039

Carolyn F Deacon

Department of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, Denmark

Abstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, liraglutide binds non-covalently to albumin, giving it a pharmacokinetic profile suitable for once-daily administration. In clinical trials of up to 1 year duration, liraglutide has been demonstrated to have beneficial effects on islet cell function, leading to improvements in glycemic control. Both fasting and postprandial glucose concentrations are lowered, and are associated with lasting reductions in HbA1c levels. Liraglutide is effective as monotherapy and in combination therapy with oral antidiabetic drugs, and reduces HbA1c by up to ∼1.5% from baseline (8.2%–8.4%). Because of the glucose-dependency of its action, there is a low incidence of hypoglycemia. Liraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials. The most common adverse events reported with liraglutide are gastrointestinal (nausea, vomiting and diarrhea). These tend to be most pronounced during the initial period of therapy and decline with time. Further clinical experience with liraglutide will reveal its long-term durability, safety and efficacy.

Keywords: liraglutide, GLP-1, incretin mimetic, type 2 diabetes

Readers of this article also read: